Arrangement, and are you guaranteeing what is the price of the drug when are you saying you are only going to get paid x if you reach a cure level or certain level of adherence. Theres some interference there, and its used as an excuse for those types of arrangement or getting out of those arrangements by pharmaceutical companies. The other is the fda approves the drug if it works. And they dont necessarily approve it saying whether it works better than things that have previously been approved or whether it doesnt work better than thing previously approved. And that can create some friction when it comes to dealing with providers who seem to want to gravitate toward the newest and the latest, even if it really doesnt turn out to work any better than some of the alternatives that have come down the pike before. So whats the solution there . More as we heard on the earlier panel, more effectiveness, information and data . I think the comparative effectiveness would really help. Then you
So that went my copay jumped from 0 to 300 that month. Those are the kind of things youre constantly trying to stay in front of as a patient. And again, i could be any of you. Right. Well, that concludes our morning session. We were going to take a onehour break now for lunch. As a reminder, you are not permitted to move around the building on your own. If you want to purchase lunch in the cafeteria on the top floor, go to the registration desk. You can go outside and to the left. Well presume promptly at 12 45. Join me first of all the in thanking this panel and wishing heather all the best in your treatment. Thank you. [ applause ] up next, more from the department of health and Human Services forum on pharmaceutical noin vags and drug costs. Panelists share ideas on improving access and affordability to high quality drugs. Welcome back, everybody. I hope you enjoyed your lunch and your break. Were now going to move on to our next presentation. And i have the pleasure of introducing